Tata Elxsi stock price target lowered to INR3,800 by JPMorgan

JPMorgan has lowered its price target on Tata Elxsi Ltd (NS:TELX) to INR3,800 from INR4,000, while maintaining an Underweight rating, following the company's fourth consecutive quarter of disappointing results. The first-quarter performance missed expectations with revenue declining 3.9% quarter-over-quarter in constant currency, driven by weakness in the Media & Telecom and Healthcare segments. Consequently, JPMorgan reduced its earnings estimates for Tata Elxsi by 3-5% for fiscal years 2026 through 2028, reflecting ongoing challenges in Healthcare and mixed outlooks, particularly tariff-related uncertainty in Automotive, despite management's expectation for Telecom growth.

Analysis

JPMorgan has reiterated its bearish stance on Tata Elxsi Ltd by maintaining an "Underweight" rating and lowering its price target to INR 3,800 from INR 4,000. This decision is underpinned by the company's first-quarter results, which marked the fourth consecutive quarter of missing revenue and margin expectations. The top-line performance was particularly weak, with a 3.9% quarter-over-quarter decline in constant currency revenue, driven by significant contractions in the Media & Telecom segment, which fell 5.5%, and the Healthcare segment, which dropped 6.7%. While the key Automotive segment showed signs of stabilization with flat performance, its outlook remains mixed due to a gradual ramp-up of large deals and persistent tariff-related demand uncertainty in the U.S. market. Despite management's guidance for a return to growth in Telecom from the second quarter, ongoing client-specific challenges in Healthcare and the revised earnings estimates, which JPMorgan has cut by 3-5% for fiscal years 2026-2028, signal continued fundamental pressures.

Key Decisions for Investors

• Given the maintained 'Underweight' rating and four consecutive quarters of underperformance, investors should critically reassess their holdings in Tata Elxsi as near-term catalysts appear limited.
• Potential investors should weigh management's optimistic guidance for a Telecom rebound against the tangible risks of ongoing weakness in the Healthcare segment and tariff-related headwinds in the Automotive division.
• Closely monitor upcoming earnings for concrete evidence of the guided ramp-up in large Telecom deals, as this will be a critical proof point for any potential turnaround in the company's growth trajectory.